Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow OGN by emailGet an email when OGN pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about OGN, unsubscribe in one click. Privacy
📣 What OGN Says Is Next
early 2027 · “The merger is expected to close in early 2027, subject to customary closing conditions, including receipt of required regulatory approvals and approval by Organon stockholders. · In light of the pending merger, Organon will not be providing financial guidance or hosting quarterly earnings calls.”
Company press release, Apr 30, 2026 · SEC filing
early 2027 · “The transaction is expected to close in early 2027, subject to customary conditions, including regulatory approvals and Organon stockholder approval.”
Company press release, Apr 27, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full OGN picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OGN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.